8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Jan 12, 2026·SEC
Dyne Therapeutics, Inc.(DYN)Earnings, Financials & Key Ratios
DYN•NASDAQ
Price updated Jun 19, 2026
AboutDyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..Show more
- Revenue$0
- EBITDA-$466M-36.4%
- Net Income-$446M-40.6%
- EPS (Diluted)-3.47-3.0%
- ROE-55.71%+36.7%
DYN Key Insights
Dyne Therapeutics, Inc. (DYN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 50.0% over 5 years
- ✗Shares diluted 36.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DYN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DYN Price & Volume
Dyne Therapeutics, Inc. (DYN) stock price & volume — 10-year historical chart
Loading chart...
DYN Growth Metrics
Dyne Therapeutics, Inc. (DYN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.04%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM10.31%
Return on Capital
10 Years-52.73%
5 Years-71.46%
3 Years-88.69%
Last Year-52.45%
DYN Recent Earnings
Dyne Therapeutics, Inc. (DYN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.73+5.5%
$0.77
Rev
—
—
Q2 2026
Mar 2, 2026Metric
Actual
Est
EPS
$0.76-2.7%
$0.74
Rev
—
—
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.76+6.2%
$0.81
Rev
—
—
Q3 2025
Jul 28, 2025Metric
Actual
Est
EPS
$0.97+2.0%
$0.99
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.73vs $0.77+5.5% | — |
| Q2 2026 | Mar 2, 2026 | $0.76vs $0.74-2.7% | — |
| Q4 2025 | Nov 5, 2025 | $0.76vs $0.81+6.2% | — |
| Q3 2025 | Jul 28, 2025 | $0.97vs $0.99+2.0% | — |
Based on last 12 quarters of dataView full earnings history →
DYN Peer Comparison
Dyne Therapeutics, Inc. (DYN) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BMRN | 10.52B | 54.69 | 30.38 | 12.87% | 8.29% | 4.41% | 0.11 | |
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 |
Compare DYN vs Peers
Dyne Therapeutics, Inc. (DYN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DYN Income Statement
Dyne Therapeutics, Inc. (DYN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 506M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | -62.96% | -100% | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 2.93B | 24K | 271K | 700K | 0 | 0 | 2.46M | 2.24M | 2.05M | 1.07M |
COGS % of Revenue | 579.45% | - | - | - | - | - | - | - | - | - |
Gross Profit | -2.43B▲ 0% | -24K▲ 100.0% | -271K▼ 1029.2% | -700K▼ 158.3% | 0▲ 100.0% | 0▲ 0% | -2.46M▲ 0% | -2.24M▲ 8.9% | -2.05M▲ 8.6% | -1.07M▲ 0% |
Gross Margin % | -479.45% | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | -165.14% | 100% | -1029.17% | -158.3% | 100% | - | - | 8.86% | 8.65% | - |
Operating Expenses | 189M | 4.79M | 13.83M | 57.95M | 150.03M | 170.96M | 239.7M | 341.64M | 466.13M | 470.57M |
OpEx % of Revenue | 37.35% | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 189M | 517K | 2.79M | 12.75M | 28.72M | 28.2M | 31.4M | 62.48M | 69.85M | 78.31M |
SG&A % of Revenue | 37.35% | - | - | - | - | - | - | - | - | - |
Research & Development | 0 | 4.28M | 11.04M | 45.2M | 121.31M | 142.76M | 210.76M | 281.41M | 398.33M | 392.77M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | -21K | 0 | 0 | 0 | 0 | -2.46M | -2.24M | 0 | -521K |
Operating Income | -412M▲ 0% | -4.79M▲ 98.8% | -13.83M▼ 188.3% | -58.65M▼ 324.2% | -150.03M▼ 155.8% | -170.96M▼ 14.0% | -242.16M▼ 41.6% | -343.89M▼ 42.0% | -468.18M▼ 36.1% | -471.09M▲ 0% |
Operating Margin % | -81.42% | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | 35.63% | 98.84% | -188.34% | -324.18% | -155.81% | -13.96% | -41.65% | -42.01% | -36.15% | - |
EBITDA | 455M | -4.77M | -13.55M | -57.95M | -148.94M | -169.28M | -239.7M | -341.64M | -466.13M | -468.99M |
EBITDA Margin % | 89.92% | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | 261.11% | -101.05% | -184.11% | -327.5% | -157.02% | -13.66% | -41.6% | -42.53% | -36.44% | -18.64% |
D&A (Non-Cash Add-back) | 867M | 24K | 271K | 700K | 1.09M | 1.68M | 2.46M | 2.24M | 2.05M | 2.1M |
EBIT | 78M | -4.81M | -14.86M | -59.04M | -150.03M | -170.96M | -235.94M | -317.42M | -440.02M | -442.93M |
Net Interest Income | 0 | 0 | 290K | -340K | 742K | 0 | 7.64M | 26.92M | 23.67M | 21.12M |
Interest Income | 0 | 5K | 290K | 56K | 742K | 2.92M | 7.64M | 26.92M | 29.86M | 31.52M |
Interest Expense | 616M | 5K | 0 | 396K | 0 | 2.92M | 0 | 0 | 6.19M | 10.39M |
Other Income/Expense | -126M | -16K | -1.03M | -790K | 734K | 2.86M | 6.22M | 26.47M | 21.97M | 19.38M |
Pretax Income | -538M▲ 0% | -4.81M▲ 99.1% | -14.86M▼ 208.9% | -59.44M▼ 300.0% | -149.29M▼ 151.2% | -168.1M▼ 12.6% | -235.94M▼ 40.4% | -317.42M▼ 34.5% | -446.21M▼ 40.6% | -451.71M▲ 0% |
Pretax Margin % | -106.32% | - | - | - | - | - | - | - | - | - |
Income Tax | -610M | -11K | 0 | -700K | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 113.38% | 0.23% | 0% | 1.18% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | 76M▲ 0% | -4.81M▼ 106.3% | -13.54M▼ 181.4% | -58.74M▼ 333.9% | -149.29M▼ 154.2% | -168.1M▼ 12.6% | -235.94M▼ 40.4% | -317.42M▼ 34.5% | -446.21M▼ 40.6% | -451.71M▲ 0% |
Net Margin % | 15.02% | - | - | - | - | - | - | - | - | - |
Net Income Growth % | 106.13% | -106.33% | -181.36% | -333.93% | -154.17% | -12.6% | -40.36% | -34.54% | -40.58% | -23.04% |
Net Income (Continuing) | 76M | -4.81M | -14.86M | -58.74M | -149.29M | -168.1M | -235.94M | -317.42M | -446.21M | -451.71M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.47▲ 0% | -0.47▼ 200.0% | -0.30▲ 36.2% | -1.24▼ 313.3% | -2.93▼ 136.3% | -3.23▼ 10.2% | -3.95▼ 22.3% | -3.37▲ 14.7% | -3.47▼ 3.0% | -2.74▲ 0% |
EPS Growth % | 104.89% | -200% | 36.17% | -313.33% | -136.29% | -10.24% | -22.29% | 14.68% | -2.97% | 10.31% |
EPS (Basic) | 0.47 | -0.47 | -0.30 | -1.24 | -2.93 | -3.23 | -3.95 | -3.37 | -3.47 | - |
Diluted Shares Outstanding | 162M | 10.32M | 45.42M | 47.27M | 50.9M | 51.98M | 59.68M | 94.14M | 128.44M | 165.04M |
Basic Shares Outstanding | 162M | 10.32M | 45.42M | 47.27M | 50.9M | 51.98M | 59.68M | 94.14M | 128.44M | 165.04M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
DYN Balance Sheet
Dyne Therapeutics, Inc. (DYN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.52B | 8.16M | 14.76M | 349.09M | 382.39M | 265.59M | 129.38M | 659.28M | 1.13B | 1.02B |
Cash & Short-Term Investments | 397M | 8.12M | 14.63M | 345.31M | 376.57M | 256.01M | 123.1M | 642.27M | 1.11B | 972.16M |
Cash Only | 365M | 8.12M | 14.63M | 300.85M | 200.82M | 172.15M | 121.63M | 435.45M | 893.37M | 753.1M |
Short-Term Investments | 32M | 0 | 0 | 44.46M | 175.75M | 83.86M | 1.47M | 206.82M | 217.19M | 219.05M |
Accounts Receivable | 513M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | 370.05 | - | - | - | - | - | - | - | - | - |
Inventory | 445M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 55.4 | - | - | - | - | - | - | - | - | - |
Other Current Assets | 169M | 0 | 0 | 0 | 0 | 9.58M | 6.28M | 17.01M | 16.02M | 48.87M |
Total Non-Current Assets | 10.25B | 110K | 1.68M | 4.25M | 43.27M | 40.73M | 35.71M | 31.95M | 60.37M | 58.92M |
Property, Plant & Equipment | 8.88B | 110K | 1.49M | 1.95M | 40.96M | 38.41M | 33.39M | 30.01M | 44.77M | 43.33M |
Fixed Asset Turnover | 0.06x | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 772M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 26M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | -31M | 0 | 191K | 2.3M | 2.31M | 2.32M | 2.31M | 1.94M | 15.6M | 15.59M |
Total Assets | 11.77B▲ 0% | 8.27M▼ 99.9% | 16.44M▲ 98.8% | 353.33M▲ 2049.8% | 425.66M▲ 20.5% | 306.32M▼ 28.0% | 165.08M▼ 46.1% | 691.23M▲ 318.7% | 1.19B▲ 71.7% | 1.08B▲ 0% |
Asset Turnover | 0.04x | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -9.82% | -99.93% | 98.79% | 2049.76% | 20.47% | -28.04% | -46.11% | 318.72% | 71.72% | 122.53% |
Total Current Liabilities | 1.05B | 711K | 2.36M | 10.97M | 28.72M | 28.09M | 51.09M | 42.26M | 50.63M | 51.25M |
Accounts Payable | 367M | 518K | 1.26M | 3.44M | 4.03M | 5.26M | 22.94M | 6.56M | 8.08M | 10.78M |
Days Payables Outstanding | 45.69 | 7.88K | 1.69K | 1.79K | - | - | 3.4K | 1.07K | 1.44K | 3.83K |
Short-Term Debt | 105M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5M | 5.03M |
Deferred Revenue (Current) | 7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 570M | 9K | 562K | 0 | 0 | 0 | 0 | 30.85M | 37.55M | 35.44M |
Current Ratio | 1.45x | 11.47x | 6.26x | 31.83x | 13.31x | 9.46x | 2.53x | 15.60x | 22.25x | 19.92x |
Quick Ratio | 1.03x | 11.47x | 6.26x | 31.83x | 13.31x | 9.46x | 2.53x | 15.60x | 22.25x | 19.92x |
Cash Conversion Cycle | 379.76 | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 8.48B | 12.44M | 42K | 0 | 28.74M | 25.87M | 22.7M | 19.14M | 164.2M | 163.65M |
Long-Term Debt | 8.33B | 3.38M | 0 | 0 | 0 | 0 | 0 | 0 | 15.28M | 14.27M |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 28.74M | 25.87M | 22.7M | 19.14M | 0 | 33.54M |
Deferred Tax Liabilities | 7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 146M | 9.06M | 42K | 0 | 0 | 0 | 0 | 0 | 148.92M | 149.38M |
Total Liabilities | 9.87B | 13.15M | 2.4M | 10.97M | 57.47M | 53.96M | 73.79M | 61.4M | 214.83M | 214.9M |
Total Debt | 8.43B | 3.38M | 0 | 0 | 32.64M | 30.48M | 27.41M | 23.99M | 20.28M | 19.3M |
Net Debt | 8.07B | -4.75M | -14.63M | -300.85M | -168.19M | -141.66M | -94.21M | -411.46M | -873.09M | -733.8M |
Debt / Equity | 4.44x | - | - | - | 0.09x | 0.12x | 0.30x | 0.04x | 0.02x | 0.02x |
Debt / EBITDA | 18.53x | - | - | - | - | - | - | - | - | -0.04x |
Net Debt / EBITDA | 17.73x | - | - | - | - | - | - | - | - | 1.56x |
Interest Coverage | 0.13x | -962.20x | - | -149.09x | - | -58.61x | - | - | -71.06x | -42.61x |
Total Equity | 1.9B▲ 0% | -4.88M▼ 100.3% | 14.04M▲ 387.7% | 342.37M▲ 2339.2% | 368.2M▲ 7.5% | 252.36M▼ 31.5% | 91.29M▼ 63.8% | 629.84M▲ 589.9% | 972.13M▲ 54.3% | 865.05M▲ 0% |
Equity Growth % | -6.91% | -100.26% | 387.68% | 2339.21% | 7.54% | -31.46% | -63.83% | 589.92% | 54.35% | 55.42% |
Book Value per Share | 11.73 | -0.47 | 0.31 | 7.24 | 7.23 | 4.86 | 1.53 | 6.69 | 7.57 | 5.24 |
Total Shareholders' Equity | 1.9B | -4.88M | 14.04M | 342.37M | 368.2M | 252.36M | 91.29M | 629.84M | 972.13M | 865.05M |
Common Stock | 1M | 1K | 1K | 5K | 6K | 6K | 6K | 10K | 16K | 16K |
Retained Earnings | -1.85B | -4.89M | -19.75M | -79.18M | -228.47M | -396.57M | -632.51M | -949.93M | -1.4B | -1.52B |
Treasury Stock | 0 | -7K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 32M | -24K | 0 | -27K | -269K | -571K | 0 | 6K | 0 | -137K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DYN Cash Flow Statement
Dyne Therapeutics, Inc. (DYN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 585M | -4.16M | -11.83M | -46.51M | -119.56M | -153.65M | -188.16M | -292.37M | -403.21M | -442.24M |
Operating CF Margin % | 115.61% | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -13.46% | -100.71% | -184.2% | -293% | -157.08% | -28.51% | -22.46% | -55.38% | -37.91% | -163.7% |
Net Income | 76M | -4.81M | -14.86M | -59.44M | -149.29M | -168.1M | -235.94M | -317.42M | -446.21M | -451.71M |
Depreciation & Amortization | 867M | 24K | 271K | 700K | 1.09M | 1.68M | 1.67M | -1.93M | 2.05M | 2.07M |
Stock-Based Compensation | 0 | 1K | 26K | 6.59M | 17.54M | 15.18M | 19.97M | 45.86M | 45.85M | 34.83M |
Deferred Taxes | 610M | 0 | 0 | 12K | 2.59M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 584M | 21K | 1.32M | 514K | -746K | 2.97M | -173K | 607K | -1.49M | 9.99M |
Working Capital Changes | -1.6B | 601K | 1.41M | 5.11M | 9.26M | -5.38M | 26.31M | -19.49M | -3.4M | -37.42M |
Change in Receivables | -47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 110M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 46M | 635K | 1.69M | 8.57M | 13.7M | -1.24M | 22.97M | -8.96M | 8.25M | 12.05M |
Cash from Investing | -2.76B | -134K | -1.65M | -45.66M | -137.89M | 87.2M | 83.31M | -204.08M | -28.75M | -32.6M |
Capital Expenditures | -224M | -134K | -1.65M | -1.16M | -3.62M | -3.07M | -729K | -2.38M | -1.92M | -19.95M |
CapEx % of Revenue | 44.27% | - | - | - | - | - | - | - | - | - |
Acquisitions | -3.32B | 0 | 0 | 0 | 8K | 34K | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 784M | 0 | 0 | 0 | -8K | -34K | 0 | 35K | -18.76M | 54K |
Cash from Financing | -1.3B | 12.42M | 19.99M | 380.69M | 157.82M | 37.39M | 54.32M | 809.89M | 890.31M | 756.13M |
Debt Issued (Net) | 0 | 0 | 0 | -64K | 0 | 0 | 0 | 0 | 147.7M | 153.91M |
Equity Issued (Net) | 0 | 7.42M | 19.99M | 381.17M | 157.24M | 36.86M | 52.37M | 773.05M | 742.61M | 602.25M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -1.3B | 5M | 0 | -420K | 584K | 529K | 1.95M | 36.84M | 0 | -30K |
Net Change in Cash | -3.47B▲ 0% | 12.42M▲ 100.4% | 6.51M▼ 47.6% | 288.52M▲ 4333.3% | -99.63M▼ 134.5% | -29.05M▲ 70.8% | -50.52M▼ 73.9% | 313.45M▲ 720.4% | 458.35M▲ 46.2% | 281.28M▲ 0% |
Free Cash Flow | 361M▲ 0% | -4.3M▼ 101.2% | -13.48M▼ 213.7% | -47.67M▼ 253.6% | -123.18M▼ 158.4% | -156.71M▼ 27.2% | -188.89M▼ 20.5% | -294.75M▼ 56.0% | -405.13M▼ 37.4% | -462.19M▲ 0% |
FCF Margin % | 71.34% | - | - | - | - | - | - | - | - | - |
FCF Growth % | 3.14% | -101.19% | -213.66% | -253.6% | -158.41% | -27.22% | -20.53% | -56.04% | -37.45% | -43.14% |
FCF per Share | 2.23 | -0.42 | -0.30 | -1.01 | -2.42 | -3.02 | -3.16 | -3.13 | -3.15 | -2.80 |
FCF Conversion (FCF/Net Income) | 7.70x | 0.87x | 0.87x | 0.79x | 0.80x | 0.91x | 0.80x | 0.92x | 0.90x | 1.02x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DYN Key Ratios
Dyne Therapeutics, Inc. (DYN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 3.85% | -0.51% | -295.64% | -32.96% | -42.02% | -54.18% | -137.31% | -88.03% | -55.71% | -58.28% |
Return on Invested Capital (ROIC) | -3.22% | -0.07% | - | -214.99% | -93.17% | -82.53% | -337.02% | -239.41% | -221.25% | -208.93% |
Gross Margin | -479.45% | - | - | - | - | - | - | - | - | - |
Net Margin | 15.02% | - | - | - | - | - | - | - | - | - |
Debt / Equity | 4.44x | - | - | - | 0.09x | 0.12x | 0.30x | 0.04x | 0.02x | 0.02x |
Interest Coverage | 0.13x | -962.20x | - | -149.09x | - | -58.61x | - | - | -71.06x | -42.61x |
FCF Conversion | 7.70x | 0.87x | 0.87x | 0.79x | 0.80x | 0.91x | 0.80x | 0.92x | 0.90x | 1.02x |
Revenue Growth | -62.96% | -100% | - | - | - | - | - | - | - | - |
Related:DYN Dividend History·DYN Revenue History·DYN Price History·DYN P/E History·DYN Financial Ratios·DYN Institutional Holders
DYN SEC Filings & Documents
Dyne Therapeutics, Inc. (DYN) SEC filings — annual & quarterly reports (10-K, 10-Q)
DYN Frequently Asked Questions
Dyne Therapeutics, Inc. (DYN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Dyne Therapeutics, Inc. (DYN) grew revenue by 0.0% over the past year. Growth has been modest.
Dyne Therapeutics, Inc. (DYN) reported a net loss of $451.7M for fiscal year 2025.
Dividend & Returns
Dyne Therapeutics, Inc. (DYN) has a return on equity (ROE) of -55.7%. Negative ROE indicates the company is unprofitable.
Dyne Therapeutics, Inc. (DYN) had negative free cash flow of $462.2M in fiscal year 2025, likely due to heavy capital investments.